SureTrader SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 1/24/2017 12:08:24 PM - Followers: 63 - Board type: Free - Posts Today: 1

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
GALT News: Statement of Changes in Beneficial Ownership (4) 01/20/2017 04:47:50 PM
GALT News: Statement of Beneficial Ownership (sc 13d) 01/18/2017 04:33:11 PM
GALT News: Statement of Changes in Beneficial Ownership (4) 01/09/2017 05:25:49 PM
GALT News: Statement of Changes in Beneficial Ownership (4) 01/09/2017 04:58:57 PM
GALT News: Amended Statement of Changes in Beneficial Ownership (4/a) 01/09/2017 04:57:05 PM
PostSubject
#2686   MRK would seem like a great possible partner gss2003 01/24/17 12:08:23 PM
#2685   Don't think any are in the money. From jmh0602 01/23/17 12:54:58 PM
#2684   In the money? What is the strike? Jumpinjackas 01/22/17 10:17:12 PM
#2683   The only other company is LJPC. But Chess Master 01/22/17 02:24:28 PM
#2682   The strike is 5.63 and the expiration is Chess Master 01/22/17 02:11:51 PM
#2681   There is a 98% chance of expiration or Chess Master 01/22/17 02:09:15 PM
#2680   I've been looking at other companies working on jmh0602 01/22/17 12:58:20 PM
#2679   If they extend those warrants I'll be PISSED! thefamilyman 01/21/17 03:11:46 PM
#2678   Is it $5.37 or something by 3/31/17? Either gss2003 01/21/17 10:34:33 AM
#2677   I think warrants will expire worthless Jumpinjackas 01/21/17 03:28:16 AM
#2676   See here's the irony of it all. Chess Master 01/20/17 02:30:42 PM
#2675   Not sure, haven' been here as long. gss2003 01/20/17 01:34:42 PM
#2674   I will opine on the combination therapy. Chess Master 01/20/17 01:33:03 PM
#2673   Isn't the cancer trial using combo therapy with jmh0602 01/20/17 12:47:11 PM
#2672   Correction, study not run by Merck,by Providence. gss2003 01/20/17 12:04:25 PM
#2671   Agree in theory, but this is a small gss2003 01/20/17 11:41:38 AM
#2670   Looks like a swag. If you do Chess Master 01/20/17 11:33:59 AM
#2669   Yes, I read it, of course. I have Darwinian 01/20/17 11:33:48 AM
#2668   Chess, I agree, seems like news that GR-MD-02 in gss2003 01/20/17 09:39:54 AM
#2667   Didn't you read that seeking alpha blog. Chess Master 01/19/17 07:50:24 PM
#2666   Question now is, what does Uline know? Or Darwinian 01/19/17 12:37:35 PM
#2665   Agree, MRK should buy it, accelerate the trials gss2003 01/18/17 10:13:34 PM
#2664   I bought in three years ago so I jmh0602 01/18/17 08:27:38 PM
#2663   Like it says connect the dots. No Chess Master 01/18/17 06:14:46 PM
#2662   could be they're only putting in a low jmh0602 01/18/17 04:44:06 PM
#2661   Wow, why wouldn't MRK just take them out gss2003 01/18/17 04:26:52 PM
#2660   http://seekingalpha.com/instablog/19785151-bioman135/4951078-major-immunotherapy Chess Master 01/18/17 04:11:35 PM
#2659   There is clearly positioning or what others call Chess Master 01/18/17 02:12:30 PM
#2658   It is crazy to keep the warrants and Chess Master 01/17/17 07:07:36 PM
#2657   I don't know. I think it was "Chessmaster" Darwinian 01/16/17 05:29:32 PM
#2656   Warrants-I think i get it but now have jmh0602 01/16/17 05:09:55 PM
#2655   GALTU is either 2 shares stock and 1 Darwinian 01/16/17 04:53:47 PM
#2654   I'm trying to make sense of this. jmh0602 01/16/17 02:10:56 PM
#2653   The $50 mil CNAT deal moved to $6. Chess Master 01/13/17 07:11:52 PM
#2652   I don't. I sold all my Warrants after thefamilyman 01/13/17 06:59:24 PM
#2651   I think the licensing deal is needed to gss2003 01/13/17 04:56:31 PM
#2650   That's exactly whats going on. Because it Chess Master 01/13/17 04:00:16 PM
#2649   Hard to say. The units have been crazy Darwinian 01/13/17 01:13:42 PM
#2648   Somebody must know something. Perhaps we are within thefamilyman 01/13/17 12:24:09 PM
#2647   Whats up with the warrants ? shurtha2000 01/13/17 09:28:09 AM
#2646   Soley GALT - how are we going to Chess Master 01/08/17 09:43:13 PM
#2645   Chess, Can I join this too? Is it solely gss2003 01/06/17 12:46:46 PM
#2644   sure, I'm interested... biotech2010 01/06/17 01:25:35 AM
#2643   Hey bio - I formed a private shareholder Chess Master 01/05/17 11:40:23 PM
#2642   So I dont know precedent has been set Chess Master 01/05/17 11:34:17 PM
#2641   No sure I understand this. The price Tekterra 01/05/17 03:36:01 PM
#2640   nobody likes 90 cents a share. Galt may rickyricks 01/02/17 04:03:51 PM
#2639   I think it's 1 of 2 things: gss2003 01/02/17 03:07:53 PM
#2638   Explain how GALT's management team could possibly justify biotech2010 01/02/17 02:13:15 PM
#2637   Explain how GALT's management team could possibly justify biotech2010 01/02/17 02:13:14 PM
PostSubject